Jupiter Neurosciences Acquires U.S. Rights to ALA-002 for Up to $100 Million
Jupiter Neurosciences (NASDAQ: JUNS) has acquired exclusive U.S. rights to the drug candidate ALA-002 from PharmAla Biotech Holdings in a deal worth up to $100 million. The transaction includes an upfront payment of $3.3 million, with Jupiter paying $1.5 million in cash and $1.8 million in stock.
Topics: biotech partnership licensing agreement pharmaceuticals